The Armchair Analyst

The Armchair Analyst

5-minute daily updates on the ASX life-sciences sector.

Recent Articles

Riding the Peptidal Wave: Biotech Bounce Back

Riding the Peptidal Wave: Biotech Bounce Back

Apr 16, 2026

•

3 min read

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Apr 15, 2026

•

15 min read

When Shares Become the Vote: The 249D-ilemma

When Shares Become the Vote: The 249D-ilemma

Apr 14, 2026

•

7 min read

Telix lights up the deal docket for the ASX biotech sector

Telix lights up the deal docket for the ASX biotech sector

Apr 13, 2026

•

8 min read

While everyone is selling. Big Pharma is buying.

While everyone is selling. Big Pharma is buying.

Apr 10, 2026

•

6 min read

Market’s Rocking: A Green Day

Market’s Rocking: A Green Day

Apr 9, 2026

•

6 min read

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Apr 8, 2026

•

15 min read

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Apr 7, 2026

•

21 min read

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Mar 31, 2026

•

18 min read

Why Peptides Are Suddenly Everywhere

Why Peptides Are Suddenly Everywhere

Mar 30, 2026

•

9 min read

Crowned then Clipped: When the Raise Gets There Before the Rally

Crowned then Clipped: When the Raise Gets There Before the Rally

Mar 27, 2026

•

6 min read

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Mar 26, 2026

•

9 min read

...